BPC-157

What BPC-157 is

BPC-157, formally designated as a stable gastric pentadecapeptide, is a 15-amino-acid synthetic peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular weight ~1,419 Da) derived from a protective protein sequence isolated from human gastric juice ^[1]. It was first described and published in 1993 by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, in the Journal of Physiology, Paris ^[2]. The compound earned the name 'Body Protection Compound' in recognition of its observed cytoprotective properties across diverse tissue types in laboratory models. Its discovery grew from research into the stomach's natural mucosal defence mechanisms—specifically, efforts to isolate and characterise peptidergic factors that maintain gastrointestinal (GI) tract integrity [1, 3].

As a research compound, BPC-157 belongs to the class of synthetic cytoprotective peptides. Unlike many peptides, it is reported to be notably stable in gastric acid, which has made it an attractive subject for studying oral bioavailability in animal models ^[3]. The overwhelming majority of published research originates from the Zagreb group led by Sikiric, supplemented by a smaller number of independent replication studies, primarily from Taiwanese and Chinese laboratory groups examining tendon fibroblast biology ^[4]. BPC-157 is not a natural hormone, growth factor, or endogenous signalling molecule in the classical sense; rather, it is a stabilised fragment engineered to resist enzymatic degradation, distinguishing it from the full-length gastric protein from which its sequence was identified ^[1].

What it is being researched for

1. Gastrointestinal mucosal protection and ulcer healing

The gastrointestinal tract is the most extensively studied target for BPC-157, rooted in the peptide's origin as a gastric cytoprotective sequence ^[1]. Animal studies using ethanol-, NSAID-, restraint-stress-, and cysteamine-induced ulcer models have consistently reported that BPC-157 reduces lesion area, accelerates re-epithelialisation, and promotes granulation tissue formation compared with untreated controls [3, 5]. A key mechanistic observation is increased VEGF expression at ulcer margins in BPC-157-treated animals, suggesting that enhanced local angiogenesis drives mucosal repair ^[6]. Research has also shown that BPC-157 can counteract NSAID-induced GI damage even in the continued presence of COX inhibition, indicating a mechanism beyond simple prostaglandin restoration ^[3]. Early human-phase work involved pilot trials for ulcerative colitis and multiple sclerosis conducted in Croatia in the early 2000s, though full peer-reviewed publications of those results remain limited ^[7].

2. Tendon and ligament repair

Tendon and ligament healing represents one of the most replicated preclinical research areas for BPC-157. A 2019 review in Cell and Tissue Research concluded that all reviewed studies demonstrated consistently positive and prompt healing effects for soft tissue injuries, noting particular promise for hypovascular, hypocellular tissues such as tendons and ligaments ^[1]. In rat Achilles tendon transection models, BPC-157-treated animals showed higher biomechanical failure loads, better collagen fibre organisation, and an earlier shift from inflammatory to reparative cell populations than controls ^[4]. At the cellular level, BPC-157 has been shown to enhance tendon fibroblast outgrowth, survival, and migration, and to upregulate growth hormone receptor expression in tendon fibroblasts via FAK-paxillin signalling [4, 8]. A 2025 systematic review in orthopaedic sports medicine, covering roughly three dozen studies (nearly all preclinical), found consistent directional benefits across tendon, ligament, muscle, and bone models, while noting that the literature is dominated by rodent data from a small number of research groups ^[9].

3. Skeletal muscle injury and myotendinous junction repair

Beyond individual tissues, BPC-157 has been investigated in models of skeletal muscle injury and at the critical myotendinous junction—the interface where muscle meets tendon and a common site of athletic injury. Rat studies of quadriceps muscle detachment from bone showed that untreated animals experienced definitive healing failure, characterised by impaired ambulation and permanent joint changes, while BPC-157-treated animals showed consistent macro- and microscopic recovery across multiple time points ^[10]. Animal research in muscle injury models has also suggested beneficial effects for systemic insults such as hyperkalaemia and hypermagnesaemia, pointing to a broader cytoprotective profile beyond mechanical trauma ^[1]. A 2026 review synthesised this body of work alongside classical growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs), concluding that BPC-157 demonstrates comparable cytoprotective potential and multi-modal activity at the myotendinous and muscle-to-bone junctions ^[8].

4. Wound healing and angiogenesis

Wound healing research has identified BPC-157 as a multi-pathway agent that appears to support several sequential phases of the repair process. Studies suggest it boosts angiogenesis, stimulates collagen production, promotes cell migration and proliferation, and helps prevent excessive or chronic inflammation ^[11]. The angiogenic effect has been characterised as greater than that of standard antiulcer agents in sponge assay models ^[7]. VEGF, factor VIII, and CD34 expression peaks have been observed in early wound intervals in BPC-157-treated tissue ^[7]. The peptide's modulatory action on the nitric oxide (NO) system is considered a key driver of its vascular effects, with BPC-157 shown to interact with the Src-Caveolin-1-eNOS pathway to regulate vasomotor tone and blood flow to damaged areas [6, 12]. Preclinical evidence suggests BPC-157 may balance competing pro- and anti-angiogenic signals in a context-dependent manner, promoting repair angiogenesis while suppressing pathological vascular overgrowth in some models ^[12].

5. Neuroprotection and nervous system research

Neuroprotection is an emerging but still predominantly preclinical area of BPC-157 research. Animal studies have reported reduced haemorrhage, oedema, and oxidative damage in models of traumatic brain injury (TBI), with treated rodents demonstrating improved early motor recovery ^[13]. In hippocampal ischaemia–reperfusion models, BPC-157-treated rats showed full functional recovery on behavioural tests (Morris water maze, inclined beam-walking, lateral push) and reduced neural damage at 24 and 72 hours post-injury ^[13]. Additional preclinical work has explored effects in spinal cord compression, peripheral nerve transection, cuprizone-induced demyelination (a multiple sclerosis model), and Parkinson's- and Alzheimer's-like disturbances in rodents ^[12]. Proposed mechanisms include modulation of the dopaminergic and serotonergic systems, NO pathway interaction, and anti-inflammatory effects in CNS tissue ^[9]. It is critical to note that no published human clinical trials confirm neuroprotective benefits; this remains a research-stage area requiring well-controlled human study [5, 14].

6. Cardiovascular and haemodynamic effects

Preclinical cardiovascular research has examined BPC-157's influence on blood pressure regulation and vascular function. Studies report that the peptide modulates vasomotor tone through the Src-Caveolin-1-endothelial nitric oxide synthase (eNOS) pathway, influencing both NO production and downstream vascular relaxation ^[6]. In animal models of stomach perforation complicated by intracranial hypertension, portal hypertension, and aortic hypotension, BPC-157 was reported to markedly counteract pressure disturbances and facilitate stomach healing simultaneously ^[13]. The ability to interact with the NO system bidirectionally—supporting eNOS-driven vasodilation while also moderating excessive iNOS activity in inflamed tissue—has been highlighted as a distinguishing feature of the compound's cardiovascular pharmacology ^[12]. These findings are entirely preclinical, and their relevance to human cardiovascular physiology has not been established.

How it is thought to work

BPC-157 does not appear to act through a single receptor or target; instead, researchers have characterised it as a multi-pathway tissue-repair peptide ^[9]. The most robustly described mechanism is pro-angiogenic activity mediated via upregulation of vascular endothelial growth factor (VEGF) expression, stimulating endothelial cell proliferation, capillary formation, and tissue revascularisation at injury sites [6, 11]. This angiogenic activity is considered functionally important because many tissues studied—tendons, ligaments, gastric mucosa—depend on adequate blood supply for meaningful repair, and BPC-157's ability to recruit new vasculature may explain a large share of its downstream healing phenotype ^[8]. At the cellular level, BPC-157 has been shown to activate the FAK-paxillin signalling pathway, which governs cell adhesion, migration, and survival in fibroblasts and tenocytes, and to upregulate growth hormone receptor expression, sensitising cells to endogenous growth signals [4, 8].

A second major mechanistic pillar is modulation of the nitric oxide (NO) system. Research indicates that BPC-157 activates the Src-Caveolin-1-eNOS signalling cascade, effectively 'unlocking' constitutive nitric oxide synthase to allow a regulated release of NO that supports vasodilation, microvascular perfusion, and the initiation of downstream repair cascades [6, 12]. Crucially, this NO modulation appears to be homeostatic rather than simply stimulatory—in inflammatory contexts, BPC-157 has been observed to reduce excessive inducible NOS (iNOS) activity that would otherwise generate damaging peroxynitrite, while restoring constitutive NOS function needed for mucosal and vascular integrity ^[7]. Additional reported mechanisms include anti-inflammatory effects (reduction of pro-inflammatory cytokine expression), antioxidant activity (counteraction of free radical formation), and stabilisation of vascular permeability in injury models [11, 12]. Taken together, these pathways form a picture of a compound that acts as a broad regulator of the early-to-mid healing cascade rather than as a narrow pharmacological agonist.

Where the evidence stands

The evidence base for BPC-157 is extensive at the preclinical level but remains strikingly thin in human populations. Hundreds of animal studies—predominantly in rats and mice—have examined the peptide across gastrointestinal, musculoskeletal, neurological, and vascular injury models, with the 2019 Cell and Tissue Research review and the 2025 systematic review in orthopaedic sports medicine both concluding that preclinical findings are consistently directionally positive [1, 9]. A notable limitation is that the large majority of this literature originates from a single research group at the University of Zagreb, raising questions about independent replication; a 2025 narrative review in Inflammopharmacology explicitly highlighted this concentration and called for broader independent study ^[5]. Mechanistic work from independent Taiwanese groups on tendon fibroblasts (FAK-paxillin, growth hormone receptor) provides partial independent corroboration at the cellular level [4, 8], and a 2025 multifunctionality review in Pharmaceuticals synthesised available biological and patent data across multiple organ systems ^[14].

In humans, the evidence is minimal. As of 2026, no large-scale, peer-reviewed Phase I–III randomised controlled trials have been published for any indication ^[5]. Only three small pilot human studies exist: a retrospective observational study reporting knee pain improvement in a subset of patients treated with BPC-157 injections ^[9]; a study involving patients with interstitial cystitis that reported no adverse events; and a 2025 IRB-approved intravenous safety pilot in two healthy adults that found no adverse changes in cardiac, hepatic, renal, or metabolic biomarkers and concluded the infusion was well-tolerated ^[15]. The n=2 design of the safety pilot is an obvious and acknowledged limitation—two participants cannot establish safety in any meaningful population sense ^[15]. A Phase I pharmacokinetics trial registered on ClinicalTrials.gov (NCT02637284) was listed as cancelled before quality-control review ^[9]. The FDA has stated it lacks sufficient information to conclude that compounded BPC-157 would be safe in humans, and it is not approved by the FDA, EMA, or Health Canada for any indication ^[14]. The angiogenic mechanism that drives much of the preclinical healing data also raises a theoretical, unresolved question about tumour-supporting vascular activity; no human data exist in either direction on oncological risk [7, 12].

Frequently asked questions

What is BPC-157 and where does it come from?

BPC-157 is a synthetic 15-amino-acid peptide whose sequence was derived from a protective protein found in human gastric juice. It was first published in 1993 by researcher Predrag Sikiric at the University of Zagreb. The 'Body Protection Compound' name reflects its observed cytoprotective properties in laboratory models. It is manufactured synthetically for research purposes rather than extracted directly from biological material.

Has BPC-157 been tested in human clinical trials?

As of 2026, no large-scale, peer-reviewed Phase I–III randomised controlled trials of BPC-157 have been published for any indication. Only three small pilot human studies exist, including a 2025 intravenous safety study in two healthy adults that found no adverse events, a small retrospective knee-pain observational study, and a cystitis pilot. Early ulcerative colitis trials were conducted in Croatia, but full peer-reviewed results are limited. The human evidence base is therefore considered insufficient for clinical conclusions.

Is BPC-157 approved by the FDA or Health Canada?

No. BPC-157 is not approved by the U.S. Food and Drug Administration (FDA), Health Canada, or the European Medicines Agency (EMA) for any medical indication. The FDA has noted that it lacks sufficient information to determine whether compounded BPC-157 would be safe in humans. It is classified and sold as a research peptide, not as a licensed medicine.

What does BPC-157 research show for tendon and ligament injuries?

Preclinical studies in rodent models consistently report that BPC-157 promotes tendon and ligament healing by enhancing fibroblast activity, stimulating angiogenesis, and activating FAK-paxillin cell-migration pathways. A 2025 systematic review covering approximately three dozen studies found consistent directional benefits. However, virtually all data come from animal models, and no controlled human trials have confirmed these effects in people with tendon or ligament injuries.

How is BPC-157 thought to work at the molecular level?

Research points to several intersecting mechanisms: BPC-157 upregulates VEGF to stimulate new blood vessel formation, activates the FAK-paxillin pathway to promote cell migration and survival, modulates the nitric oxide (NO) system via the Src-Caveolin-1-eNOS cascade, and reduces pro-inflammatory cytokine activity. Growth hormone receptor expression in fibroblasts also appears to be upregulated. No single dominant receptor has been identified, suggesting a multi-pathway mode of action.

Is BPC-157 safe?

Animal studies have not identified a lethal dose at tested levels, and the compound appears to carry a low acute toxicity profile in rodent models. In the limited human pilot data available—specifically a 2025 two-person intravenous safety study—no adverse events were reported. However, long-term safety in humans has not been established through rigorous controlled trials, and the FDA has stated it cannot confirm human safety. Theoretical concerns include the possibility that its pro-angiogenic activity could interact with tumour biology, though no human data exist on this question.

What tissues has BPC-157 been studied for in animal models?

Preclinical research has examined BPC-157 across a wide range of tissues including gastric and intestinal mucosa, tendons, ligaments, skeletal muscle, bone, peripheral nerves, the central nervous system (brain and spinal cord), cornea, liver, and blood vessels. The gastrointestinal tract and musculoskeletal soft tissues represent the most extensively characterised areas, with consistent directional findings across multiple independent studies.

Does BPC-157 affect the nervous system?

Animal studies have reported neuroprotective effects in models of traumatic brain injury, spinal cord compression, ischaemic stroke, and peripheral nerve transection, including improvements in motor recovery and reduced neuronal damage. Proposed mechanisms include NO pathway modulation, dopaminergic and serotonergic system interactions, and anti-inflammatory effects in CNS tissue. No human clinical trials have confirmed neuroprotective benefits, and this area is considered early-stage research.

What are the main limitations of the current BPC-157 research?

The major limitations include: near-total reliance on rodent models whose findings do not reliably translate to humans; heavy concentration of published studies from a single research group at the University of Zagreb with limited independent replication; absence of completed, peer-reviewed Phase I–III human clinical trials; and no established safety data in human populations for long-term use. A theoretical oncological concern around its pro-angiogenic activity also remains unresolved in human studies.

Was BPC-157 ever banned by anti-doping agencies?

BPC-157 was temporarily added to the World Anti-Doping Agency (WADA) monitoring list in 2022, reflecting concern about its use by athletes seeking to accelerate injury recovery. It is not currently listed as a banned substance by WADA. It has not been approved as a therapeutic drug by any major regulatory authority, and its use in competitive sport exists outside regulated medical frameworks.

Glossary

Pentadecapeptide

A peptide composed of exactly 15 amino acids; BPC-157 is classified as a pentadecapeptide based on its 15-residue sequence.

Cytoprotection

The protection of individual cells from damage, death, or stressful stimuli; BPC-157's original characterisation was as a gastric cytoprotective agent shielding mucosal cells from injury.

Angiogenesis

The biological process by which new blood vessels are formed from pre-existing vasculature, essential for tissue repair and considered a primary mechanism through which BPC-157 may promote healing.

VEGF (Vascular Endothelial Growth Factor)

A key signalling protein that stimulates the formation of new blood vessels; BPC-157 has been shown in animal studies to upregulate VEGF expression at sites of tissue injury.

FAK-Paxillin pathway

A cell-signalling cascade involving Focal Adhesion Kinase (FAK) and the adaptor protein paxillin that regulates cell adhesion, migration, and survival; BPC-157 has been reported to activate this pathway in tendon fibroblasts.

Nitric Oxide (NO) system

A network of enzymes (including eNOS and iNOS) and signalling molecules that produce nitric oxide, a gaseous molecule regulating vascular tone, blood flow, and inflammation; BPC-157 is thought to modulate this system in a homeostatic manner.

eNOS (Endothelial Nitric Oxide Synthase)

The constitutive enzyme in endothelial cells responsible for producing nitric oxide to maintain vascular tone and promote healthy blood flow; BPC-157 has been reported to activate eNOS through the Src-Caveolin-1 pathway.

Preclinical evidence

Research findings derived from cell cultures (in vitro) or animal studies (in vivo) that have not yet been confirmed in human clinical trials; the vast majority of BPC-157 evidence is preclinical.

References

1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell and Tissue Research (2019)
2. BPC-157 — Wikipedia entry with primary discovery citation (Sikiric, J Physiol Paris, 1993) — Wikipedia / primary source: Journal of Physiology, Paris
3. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats — PubMed / World Journal of Gastroenterology (2004)
4. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts — PMC / Molecules (2014)
5. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — PubMed / Inflammopharmacology (2025)
6. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway — PMC (2020)
7. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — PMC (2021)
8. Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157 — A Review — Pharmaceuticals / MDPI (2026)
9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — Sports Health / SAGE Journals (2025)
10. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats — PMC (2025)
11. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management — PubMed (2025)
12. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions — Comment on Józwiak et al. Pharmaceuticals 2025, 18, 185 — Pharmaceuticals / MDPI (2025)
13. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect — ResearchGate / Journal of Orthopaedic Research
14. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review — PMC / Pharmaceuticals (2025)
15. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study — PubMed (2025)